{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T02:39:05Z","timestamp":1792636745562,"version":"4.5.0"},"reference-count":59,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008222","name":"Ben & Catherine Ivy Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008222","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rosalinde and Arthur Gilbert Foundation, the Alvarez Charitable Foundation, City of Hope, California Instistute of Regenerative Medicine","award":["CLIN1-14845"],"award-info":[{"award-number":["CLIN1-14845"]}]},{"name":"Rosalinde and Arthur Gilbert Foundation, the Alvarez Charitable Foundation, City of Hope, California Instistute of Regenerative Medicine","award":["CIRM CLIN2-13162"],"award-info":[{"award-number":["CIRM CLIN2-13162"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Despite innovative progress, cellular therapies have not produced durable, population-level survival gains in glioblastoma. Across 3 major modalities, engineered effectors such as chimeric antigen receptor T cell (CAR-T) and natural killer (NK) cells, immune-education platforms such as dendritic and whole-cell vaccines, and carrier cells delivering oncolytic or drug payloads, trials have shown measurable bioactivity, but durability has varied. This likely reflects systemic barriers, including therapy-induced lymphopenia, myeloid dominance, and T-cell sequestration, as well as local barriers such as antigen heterogeneity and immune suppression. To understand why some studies nevertheless showed more favorable efficacy signals, we reviewed clinical outcomes across these modalities and identified 4 recurring design features that appeared repeatedly among studies reporting more favorable survival signals: treatment in the minimal residual disease setting, a T-helper type 1 supportive context, broadened antigenic coverage, and effective immune hand-off from the initiating therapy to endogenous or adoptively transferred effectors. Across heterogeneous early-phase studies, greater feature alignment sometimes co-occurred with more favorable signals, although this retrospective pattern is descriptive and does not establish association or causality. These observations may help guide future biomarker-informed strategies and provide a practical framework for organizing multimodal trials aimed at converting transient bioactivity into more durable, polyclonal control.<\/jats:p>","DOI":"10.1093\/stcltm\/szag084","type":"journal-article","created":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:01:07Z","timestamp":1792627267000},"source":"Crossref","is-referenced-by-count":0,"title":["Cell-based therapies for malignant glioma"],"prefix":"10.1093","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9069-0206","authenticated-orcid":false,"given":"Rachael","family":"Mooney","sequence":"first","affiliation":[{"name":"Department of Stem Cell Biology and Regenerative Medicine, City of Hope Comprehensive Cancer Center and Beckman Research Institute , Duarte, CA 91010,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslam E","family":"Abd El-Fattah","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Biology and Regenerative Medicine, City of Hope Comprehensive Cancer Center and Beckman Research Institute , Duarte, CA 91010,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9444-5200","authenticated-orcid":false,"given":"Gary","family":"Ngai","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Biology and Regenerative Medicine, City of Hope Comprehensive Cancer Center and Beckman Research Institute , Duarte, CA 91010,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Lara","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Biology and Regenerative Medicine, City of Hope Comprehensive Cancer Center and Beckman Research Institute , Duarte, CA 91010,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Hammad","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University Hospitals and Case Western Reserve University , Cleveland, OH 44106,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen S","family":"Aboody","sequence":"additional","affiliation":[{"name":"Department of Stem Cell Biology and Regenerative Medicine, City of Hope Comprehensive Cancer Center and Beckman Research Institute , Duarte, CA 91010,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"2026102121520447000_szag084-B1","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s41984-024-00294-5","article-title":"Survival rate of patient with glioblastoma: a population-based study","volume":"39","author":"Sabouri","year":"2024","journal-title":"Egypt J Neurosurg"},{"key":"2026102121520447000_szag084-B2","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/neuonc\/noaf031","article-title":"Identifying appropriate external control datasets in support of future glioblastoma clinical trials leveraging external data","volume":"27","author":"Rahman","year":"2025","journal-title":"Neuro Oncol"},{"key":"2026102121520447000_szag084-B3","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3390\/ijms19102879","article-title":"Glioblastoma chemoresistance: the double play by microenvironment and blood-brain barrier","volume":"19","author":"Da Ros","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2026102121520447000_szag084-B4","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.ibneur.2025.04.007","article-title":"The emerging role of circulating tumor DNA in brain tumor research","volume":"18","author":"Chahardehi","year":"2025","journal-title":"IBRO Neurosci Rep"},{"key":"2026102121520447000_szag084-B5","doi-asserted-by":"crossref","first-page":"1507632","DOI":"10.3389\/fonc.2025.1507632","article-title":"Integrative multi-omic profiling of the neoantigen landscape of glioblastoma for the development of therapeutic vaccines reveals vast heterogeneity in immunogenic signatures","volume":"15","author":"Lin","year":"2025","journal-title":"Front Oncol"},{"key":"2026102121520447000_szag084-B6","doi-asserted-by":"crossref","first-page":"1561388","DOI":"10.3389\/fimmu.2025.1561388","article-title":"Single-cell and spatial transcriptomic insights into glioma cellular heterogeneity and metabolic adaptations","volume":"16","author":"Fu","year":"2025","journal-title":"Front Immunol"},{"key":"2026102121520447000_szag084-B7","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2026102121520447000_szag084-B8","doi-asserted-by":"publisher","first-page":"15","DOI":"10.29173\/jchla29657","article-title":"Elicit (product review)","volume":"44","author":"Kung","year":"2023","journal-title":"J Canadian Health Libraries Assoc\/Journal de L\u2019Association Des Biblioth\u00e8ques de La Sant\u00e9 Du Canada"},{"key":"2026102121520447000_szag084-B9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00701-025-06755-6","article-title":"Determinants of survival after re-resection for recurrent glioblastoma: a meta-analysis","volume":"168","author":"Baby","year":"2026","journal-title":"Acta Neurochir (Wien)"},{"key":"2026102121520447000_szag084-B10","doi-asserted-by":"crossref","first-page":"904133","DOI":"10.3389\/fimmu.2022.904133","article-title":"Advanced cell therapies for glioblastoma","volume":"13","author":"Wang","year":"2022","journal-title":"Front Immunol"},{"key":"2026102121520447000_szag084-B11","first-page":"vdab156","article-title":"A randomized phase II trial of efficacy and safety of the immunotherapy ALECSAT as an adjunct to radiotherapy and temozolomide for newly diagnosed glioblastoma","volume":"3","author":"Werlenius","year":"2021","journal-title":"Neurooncol Adv"},{"key":"2026102121520447000_szag084-B12","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2017.75.8219","article-title":"Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma","volume":"36","author":"Lang","year":"2018","journal-title":"J Clin Oncol"},{"key":"2026102121520447000_szag084-B13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13073-019-0653-7","article-title":"Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system","volume":"11","author":"Lhuillier","year":"2019","journal-title":"Genome Med"},{"key":"2026102121520447000_szag084-B14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ijrobp.2023.11.050","article-title":"Radiation therapy and Myeloid-Derived suppressor cells: breaking down their cancerous partnership","volume":"119","author":"Bergerud","year":"2024","journal-title":"Int J Radiat Oncol Biol Phy"},{"key":"2026102121520447000_szag084-B15","doi-asserted-by":"crossref","first-page":"e1434464","DOI":"10.1080\/2162402X.2018.1434464","article-title":"Temozolomide lymphodepletion enhances CAR abundance and correlates with antitumor efficacy against established glioblastoma","volume":"7","author":"Suryadevara","year":"2018","journal-title":"Oncoimmunology"},{"key":"2026102121520447000_szag084-B16","doi-asserted-by":"crossref","first-page":"111281","DOI":"10.1016\/j.jocn.2025.111281","article-title":"Unlocking therapeutic synergy: IDH inhibitors and immunotherapy combination in preclinical and clinical IDH mutant glioma models\u2014a systematic review","volume":"136","author":"Ramadas","year":"2025","journal-title":"J Clin Neurosci"},{"key":"2026102121520447000_szag084-B17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3174\/ajnr.A6358","article-title":"Response assessment in neuro-oncology criteria for gliomas: practical approach using conventional and advanced techniques","volume":"41","author":"Leao","year":"2020","journal-title":"AJNR Am J Neuroradiol"},{"key":"2026102121520447000_szag084-B18","doi-asserted-by":"crossref","first-page":"748","DOI":"10.3171\/2022.12.JNS222173","article-title":"Pseudoprogression versus true progression in glioblastoma: what neurosurgeons need to know","volume":"139","author":"Young","year":"2023","journal-title":"J Neurosurg"},{"key":"2026102121520447000_szag084-B19","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40336-017-0225-z","article-title":"Amino acid PET and MR perfusion imaging in brain tumours","volume":"5","author":"Filss","year":"2017","journal-title":"Clin Transl Imaging"},{"key":"2026102121520447000_szag084-B20","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.3390\/brainsci13111536","article-title":"Advances in glioblastoma therapy: an update on current approaches","volume":"13","author":"Angom","year":"2023","journal-title":"Brain Sci"},{"key":"2026102121520447000_szag084-B21","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.3390\/cancers17172898","article-title":"Advancing CAR T-cell therapy in solid tumors: current landscape and future directions","volume":"17","author":"Rafii","year":"2025","journal-title":"Cancers (Basel)"},{"key":"2026102121520447000_szag084-B22","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/neuonc\/noaa247","article-title":"DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival","volume":"23","author":"Dejaegher","year":"2021","journal-title":"Neuro Oncol"},{"key":"2026102121520447000_szag084-B23","doi-asserted-by":"crossref","first-page":"e0247293","DOI":"10.1371\/journal.pone.0247293","article-title":"Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: an open label, phase I\/IIa trial","volume":"16","author":"Lim","year":"2021","journal-title":"PLoS One"},{"key":"2026102121520447000_szag084-B24","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41591-025-03619-5","article-title":"Author correction: intratumoral oncolytic herpes virus G47\u0394 for residual or recurrent glioblastoma: a phase 2 trial","volume":"31","author":"Todo","year":"2025","journal-title":"Nat Med"},{"key":"2026102121520447000_szag084-B25","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1007\/s00262-016-1905-7","article-title":"Phase I\/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma","volume":"65","author":"Akasaki","year":"2016","journal-title":"Cancer Immunol Immunother"},{"key":"2026102121520447000_szag084-B26","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s12967-023-04213-4","article-title":"Suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cell gene delivery vehicles in recurrent glioblastoma multiforme: a first-in-human, dose-escalation, phase I clinical trial","volume":"21","author":"Oraee-Yazdani","year":"2023","journal-title":"J Transl Med"},{"key":"2026102121520447000_szag084-B27","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-18-0619","article-title":"Molecular analyses support the safety and activity of retroviral replicating vector Toca 511 in patients","volume":"24","author":"Hogan","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2026102121520447000_szag084-B28","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1001\/jamaoncol.2022.5370","article-title":"Association of autologous tumor lysate-loaded dendritic cell vaccination with extension of survival among patients with newly diagnosed and recurrent glioblastoma","volume":"9","author":"Liau","year":"2023","journal-title":"JAMA Oncol"},{"key":"2026102121520447000_szag084-B29","doi-asserted-by":"crossref","first-page":"2885","DOI":"10.1158\/1078-0432.CCR-15-2163","article-title":"Vaccination with irradiated autologous tumor cells mixed with irradiated GM-K562 cells stimulates antitumor immunity and T lymphocyte activation in patients with recurrent malignant glioma","volume":"22","author":"Curry","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026102121520447000_szag084-B30","doi-asserted-by":"crossref","first-page":"CNS22","DOI":"10.2217\/cns-2018-0009","article-title":"Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4 + T-lymphocyte counts","volume":"7","author":"Bota","year":"2018","journal-title":"CNS Oncol"},{"key":"2026102121520447000_szag084-B31","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1158\/1078-0432.CCR-21-2867","article-title":"A phase I study of autologous dendritic cell vaccine pulsed with allogeneicstem-like cell line lysate in patients with newly diagnosed or recurrent glioblastoma","volume":"28","author":"Hu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026102121520447000_szag084-B32","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor\u2013modified virus-specific T cells for progressive glioblastoma","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"key":"2026102121520447000_szag084-B33","doi-asserted-by":"crossref","first-page":"865779","DOI":"10.3389\/fonc.2022.865779","article-title":"Low MxA expression predicts better immunotherapeutic outcomes in glioblastoma patients receiving heat shock protein peptide complex 96 vaccination","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"2026102121520447000_szag084-B34","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1158\/1078-0432.CCR-16-1518","article-title":"Neural stem cell\u2013based anticancer gene therapy: a first-in-human study in recurrent high-grade glioma patients","volume":"23","author":"Portnow","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026102121520447000_szag084-B35","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/s41591-024-02875-1","article-title":"Locoregional delivery of IL-13R\u03b12-targeting CAR-T cells in recurrent high-grade glioma: a phase 1 trial","volume":"30","author":"Brown","year":"2024","journal-title":"Nat Med"},{"key":"2026102121520447000_szag084-B36","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","article-title":"Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma","volume":"25","author":"Burger","year":"2023","journal-title":"Neuro Oncol"},{"key":"2026102121520447000_szag084-B37","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot trial of adoptive transfer of chimeric antigen receptor\u2013transduced T cells targeting EGFRvIII in patients with glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J Immunother"},{"key":"2026102121520447000_szag084-B38","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1038\/s41417-020-00219-y","article-title":"Feasibility of intracerebrally administering multiple doses of genetically modified neural stem cells to locally produce chemotherapy in glioma patients","volume":"28","author":"Portnow","year":"2021","journal-title":"Cancer Gene Ther"},{"key":"2026102121520447000_szag084-B39","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro Oncol"},{"key":"2026102121520447000_szag084-B40","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s40478-018-0621-2","article-title":"Immunological analysis of phase II glioblastoma dendritic cell vaccine (audencel) trial: immune system characteristics influence outcome and Aaudencel up-regulates Th1-related immunovariables","volume":"6","author":"Erhart","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"2026102121520447000_szag084-B41","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1158\/1078-0432.CCR-16-2057","article-title":"Long-term survival in glioblastoma with cytomegalovirus pp65-targeted vaccination","volume":"23","author":"Batich","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026102121520447000_szag084-B42","doi-asserted-by":"crossref","first-page":"5297","DOI":"10.1158\/1078-0432.CCR-20-1082","article-title":"Once, twice, three times a finding: reproducibility of dendritic cell vaccine trials targeting cytomegalovirus in glioblastoma","volume":"26","author":"Batich","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026102121520447000_szag084-B43","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12967-017-1202-z","article-title":"A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients","volume":"15","author":"Inog\u00e9s","year":"2017","journal-title":"J Transl Med"},{"key":"2026102121520447000_szag084-B44","author":"Everson","year":". 2024;15:3882."},{"key":"2026102121520447000_szag084-B45","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3389\/fonc.2020.00702","article-title":"Effective treatment of glioblastoma multiforme with oncolytic virotherapy: a case-series","volume":"10","author":"Gesundheit","year":"2020","journal-title":"Front Oncol"},{"key":"2026102121520447000_szag084-B46","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1172\/JCI138649","article-title":"Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme","volume":"130","author":"Smith","year":"2020","journal-title":"J Clin Invest"},{"key":"2026102121520447000_szag084-B47","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S1470-2045(21)00245-X","article-title":"Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial","volume":"22","author":"Fares","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026102121520447000_szag084-B48","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1158\/1078-0432.CCR-20-3805","article-title":"Phase Ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma","volume":"27","author":"Andrews","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026102121520447000_szag084-B49","doi-asserted-by":"crossref","first-page":"2556591","DOI":"10.1080\/21645515.2025.2556591","article-title":"Phase 2 trial of personal dendritic cell vaccines in newly diagnosed glioblastoma: 3-year follow-up and correlations with survival","volume":"21","author":"Bota","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"2026102121520447000_szag084-B50","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1158\/0008-5472.CAN-17-0469","article-title":"Dendritic cells enhance polyfunctionality of adoptively transferred T cells that target cytomegalovirus in glioblastoma","volume":"78","author":"Reap","year":"2018","journal-title":"Cancer Res"},{"key":"2026102121520447000_szag084-B51","doi-asserted-by":"crossref","first-page":"5799","DOI":"10.1158\/1078-0432.CCR-19-0261","article-title":"A randomized double-blind placebo-controlled phase II trial of dendritic cell vaccine ICT-107 in newly diagnosed patients with glioblastoma","volume":"25","author":"Wen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026102121520447000_szag084-B52","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3171\/2022.12.JNS221221","article-title":"A multicenter, randomized, placebo-controlled phase IIb trial of an autologous formalin-fixed tumor vaccine for newly diagnosed glioblastomas","volume":"139","author":"Muragaki","year":"2023","journal-title":"J Neurosurg"},{"key":"2026102121520447000_szag084-B53","doi-asserted-by":"crossref","first-page":"7003","DOI":"10.18632\/oncotarget.12273","article-title":"Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea","volume":"8","author":"Kong","year":"2017","journal-title":"Oncotarget"},{"key":"2026102121520447000_szag084-B54","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41392-023-01659-2","article-title":"Characteristics of premanufacture CD8+ T cells determine CAR-T efficacy in patients with diffuse large B-cell lymphoma","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026102121520447000_szag084-B55","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.3390\/ijms25052529","article-title":"Glioblastoma therapy: past, present and future","volume":"25","author":"Obrador","year":"2024","journal-title":"Int J Mol Sci"},{"key":"2026102121520447000_szag084-B56","doi-asserted-by":"crossref","first-page":"1582296","DOI":"10.3389\/fimmu.2025.1582296","article-title":"An update on the clinical trial research of immunotherapy for glioblastoma","volume":"16","author":"Zhou","year":"2025","journal-title":"Front Immunol"},{"key":"2026102121520447000_szag084-B57","doi-asserted-by":"crossref","first-page":"188","DOI":"10.4049\/jimmunol.2300642","article-title":"Engineering challenges and opportunities in autologous cellular cancer immunotherapy","volume":"212","author":"Foley","year":"2024","journal-title":"J Immunol"},{"key":"2026102121520447000_szag084-B58","doi-asserted-by":"crossref","first-page":"139","DOI":"10.5114\/ada.2018.72585","article-title":"Wound healing complications in oncological patients: perspectives for cellular therapy","volume":"36","author":"Deptu\u0142a","year":"2019","journal-title":"Postepy Dermatol Alergol"},{"key":"2026102121520447000_szag084-B59","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/curroncol32030152","article-title":"Cognitive decline in glioblastoma (GB) patients with different treatment modalities and insights on untreated cases","volume":"32","author":"Ghadimi","year":"2025","journal-title":"Current Oncol"}],"container-title":["Stem Cells Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/15\/11\/szag084\/72259848\/szag084.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/stcltm\/article-pdf\/15\/11\/szag084\/72259848\/szag084.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T01:52:17Z","timestamp":1792633937000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/stcltm\/article\/doi\/10.1093\/stcltm\/szag084\/8965490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,16]]}},"URL":"https:\/\/doi.org\/10.1093\/stcltm\/szag084","relation":{},"ISSN":["2157-6564","2157-6580"],"issn-type":[{"value":"2157-6564","type":"print"},{"value":"2157-6580","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,10,16]]},"article-number":"szag084"}}